Ranking Profile - Fulcrum Therapeutics Inc
Introduction
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company. The company is involved in the discovery and development of small molecule therapies to unlock gene regulation in diseases. Its pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease and β Thalassemia. The company also owns a proprietary product engine FulcrumSeek, which detects drug targets that can control gene expression and treat the root cause of gene misexpression. The company’s key therapeutic areas include neuromuscular, muscular, hematologic, muscle, blood and central nervous system disorders. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Company info
Country (HQ): | United States |
Sector: | Pharmaceuticals and Healthcare |
Market Cap (US$ m): | 226 |
Revenue (US$ m): | 6 (2022) |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Fulcrum Therapeutics Inc
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release